Drugnews

Updated

Migraine: Asian pipelines and global competitors

As of 2026-11-14, Asian migraine assets include Brise’s pivotal-stage BR005, two undisclosed preclinical programs partnered by Brise and AbbVie, and Atzumi, the intranasal dihydroergotamine product from SNBL-owned Satsuma. Global comparators include atogepant, eptinezumab and rimegepant. Acute and preventive treatment are separated; a preclinical partnership is not evidence of efficacy in people.

Acute and preventive treatment

Brise’s two unnamed programs are grouped in one collaboration record without invented codes. Satsuma is US-based and controlled by a Japanese parent.

Asian companies

AssetCompanyMechanism / routeStageIndicationDeal / rightsLatest verified recordSources
BR005
Brise (China)
Oral small molecule; target not disclosed in cited release
Oral
Pivotal clinical trials; phase not specified in cited release
Acute migraine treatment in adults
No verified deal terms identified
The 11-02 issuer release lists BR005 in pivotal trials; it is separate from the 2 preclinical programs partnered with AbbVie.
Two undisclosed preclinical programs
Brise (China) / AbbVie
Targets not publicly disclosed in cited release
Not disclosed
Preclinical
Migraine; specific settings not disclosed
Agreement entered in 2024; updated in 2026; unverified amounts omitted
The 11-02 update concerns an agreement entered in 2024: Brise leads discovery and AbbVie global development and commercialization; it is not a new 2026 agreement.
STS101 / Atzumi (dihydroergotamine)
Satsuma / SNBL (Japanese parent)
Ergot derivative; serotonergic receptor activity
Intranasal powder
Approved in the US; 2025-04
Acute migraine treatment in adults
No verified deal terms identified
The company lists 2026-06 AHS abstracts and 2025-04 FDA approval; this does not establish commercial launch.

Global comparators

AssetCompanyMechanism / routeStageIndicationLatest verified recordSources
atogepant / Qulipta / Aquipta
AbbVie
CGRP receptor antagonist
Oral
Approved product; Phase 3 menstrual-migraine results
Migraine prevention; separate menstrual-migraine population
Reported Phase 3 LUNA met its primary and eight ranked secondary endpoints; results are not approval for menstrual migraine.
eptinezumab / Vyepti
Lundbeck
Anti-CGRP antibody
IV
Approved in Japan
Prevention of migraine attacks in adults
Announced Japanese MHLW marketing authorization for prevention of migraine attacks in adults.
rimegepant / Nurtec ODT
Pfizer
CGRP receptor antagonist
Orally disintegrating tablet
Approved in the US
Acute migraine / prevention of episodic migraine in adults
The cited US label is revised 2026-04; no later dated product event was verified in this review.

Events in the last 90 days

2026-08-17 – 2026-11-14

Sources and downloads

  1. Brise issuer release via PRNewswire — 2026-11-02
  2. Satsuma issuer release archive — 2026-06
  3. AbbVie LUNA topline results — 2026-09-10
  4. Lundbeck issuer release via Cision — 2026-09-16
  5. Pfizer Nurtec ODT US label — 2026-04

Information cutoff 2026-11-14